Format

Send to

Choose Destination
Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Author information

1
Digestive and Liver Disease, ENETS Center of Excellence Sant'Andrea Hospital - Sapienza University of Rome, Italy.
2
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, ENETS Center of Excellence IEO, Milan, Italy.
3
Department of Medical Oncology, Fondazione IRCCS Istituto Tumori Milano, ENETS Center of Excellence, Milan, Italy.
4
Division of Oncology, Department of Oncology and Haematology, University Hospital of Modena, Modena, Italy.
5
Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
6
Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy.
7
Department of Oncology, Azienda Ospedaliero-Universitaria Pisana and University of Pisa, Istituto Toscano Tumori, Santa Chiara Hospital, Pisa, Italy.
8
Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita e Salute University, Milan, Italy.
9
Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy.
10
Medical Oncology, AOU S. Luigi Gonzaga Regione Gonzole 10, Orbassano, Italy.
11
Struttura di Oncologia Policlinico di Monza, Monza, MB, Italy.
12
Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
13
Oncology Unit, Humanitas Clinical and Research Centre, Rozzano, Italy.
14
Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, Ancona, Italy.
15
Divisione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, ENETS Center of Excellence Naples, Italy.
16
S.C di Oncologia Medica, AOU Careggi Florence, Italy.
17
Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy.
18
Digestive and Liver Disease, ENETS Center of Excellence Sant'Andrea Hospital - Sapienza University of Rome, Italy. Electronic address: fpanzuto@ospedalesantandrea.it.

Abstract

INTRODUCTION:

Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

AIM:

To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting.

PATIENTS AND METHODS:

Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th-75th IQR).

RESULTS:

Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10 months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11 months and 8 months, respectively), and between patients who had received ≥ 3 vs ≤ 2 therapeutic approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and SD was the most frequent observed response, occurring in 43 pts (53.8%). Overall, 59 pts (73.8%) experienced AEs, which were grade 1-2 in 43 of them (72.9%), grade 3 in 15 pts (25.4%), and grade 4 in one patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity.

CONCLUSIONS:

The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases.

KEYWORDS:

Neuroendocrine tumors; Pancreas; Progressive disease; Sunitinib; Target therapy

PMID:
29361429
DOI:
10.1016/j.pan.2018.01.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center